For the Culture By The Culture
New York’s $10 million vape quarantine just put the legal market in a chokehold. Brands are sidelined, dispensaries are stuck, and regulators are fumbling a rollout already on thin ice. Here’s what happened, who’s hurting, and why trust in the system keeps going up in smoke.
The DEA is dragging its feet on cannabis rescheduling despite over 43,000 public comments and a formal Schedule III recommendation from HHS. What’s the hold-up? This deep-dive exposes the legal limbo, political stall tactics, and why America’s weed policy is still frozen in time.
Gold Flora’s implosion wasn’t a one-off—it was a warning. From ballooned budgets to influencer-backed ego trips, Big Weed’s collapse in California shows what happens when hype and hubris replace substance and sustainability. We break it all down and expose how the industry got too loud, too fast, and now can’t afford the silence.
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.
New Mexico's cannabis industry remains troubled despite increased enforcement efforts and regulatory changes. Legal businesses struggle against illegal sales and preferential treatment for larger operators. Issues such as oversaturation and regional disparities persist, with critics emphasizing the need for fair enforcement. The state's unique cannabis model is at risk without timely reforms.
Blunt glue claims to be the cleaner, more secure way to roll—but is it really safer? With zero FDA oversight, no combustion testing, and unregulated ingredients, you might be inhaling more than just smoke. We break down what’s actually in blunt glue, the risks, and whether saliva is still the safer option.
